UNLIMITED TURBO SHORT - ELI LILLY & CO | Market Closed - Euronext Paris 12:30:01 2024-06-07 EDT | ||
| 1.452 EUR | -15.43% |
|
| Current month | -28.01% | ||
| 1 month | -47.76% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 1.527 | -11.07% |
| 24-06-06 | 1.717 | -3.54% |
| 24-06-05 | 1.78 | -5.62% |
| 24-06-04 | 1.886 | +4.60% |
| 24-06-03 | 1.803 | -14.99% |
Real-time Euronext Paris
Last update June 07, 2024 at 12:30 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| DZ7NB | |
| ISIN | NLBNPNL2QYI9 |
| Date issued | 2024-04-23 |
| Strike | 916 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 3.44 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.03 € |
|---|---|
| Lowest since issue | 1.418 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
850
USD
Average target price
853.8
USD
Spread / Average Target
+0.44%
- Stock Market
- Certificates
- DZ7NB Certificat
